Research Article

Improved Efficacy of Transcatheter Arterial Chemoembolization Using Warmed Miriplatin for Hepatocellular Carcinoma

Table 1

Profile of patients and nodules.

Nonwarmed group (n = 22)Warmed group (n = 58)P value

Age, years68 (51–83)73 (50–91)0.086
Sex, n (%)
 Male/female17/5 (77.3/22.7%)34/24 (58.6/41.4%)0.10
Etiology, n (%)0.093
 HCV14 (63.6%)44 (75.9%)
 HBV1 (4.5%)7 (12.1%)
 Alcohol5 (22.7%)3 (5.2%)
 Others2 (9.2%)4 (6.8%)
Child-Pugh, n (%) 0.73
 5-6 (Class A)13 (59.1%)33 (56.9%)
 7–9 (Class B)8 (36.4%)23 (39.7%)
 10 (Class C)1 (4.5%)2 (3.4%)
 Median score6.46.5
BCLC stage, n (%)0.72
 0 (very early)0 (0%) 0 (0%)
 A (early)0 (0%) 0 (0%)
 B (intermediate)8 (36.4%) 21 (36.2%)
 C (advanced)12 (54.5%) 36 (62.1%)
 D (terminal)2 (9.1%) 1 (1.7%)
PS, n (%)0.15
 06 (27.3%) 23 (39.7%)
 113 (59.1%) 33 (56.9%)
 22 (9.1%) 2 (3.4%)
 31 (4.5%)0 (0%)
AFP (ng/mL)282.8 ± 723.1 415.5 ± 1454.3 0.80
DCP (mAU/mL)1562.6 ± 5241.2581.3 ± 2913.80.15
Nodule size (mm2) 388.6 ± 398.0383.1 ± 468.00.72
History of TACE18 (81.8%)32 (55.2%)0.038*
 Agent
  EPI alone8/18 (44.4%)4/32 (12.5%)
  CDDP alone6/18 (33.3%)12/32 (37.5%)
  MPT alone0/18 (0%)5/32 (15.6%)
  Multiple agents 4/18 (22.3%)11/32 (34.4%)
 Number of sessions0.087
  111/18 (61.1%) 17/32 (53.1%)
  24/18 (22.2%)9/32 (28.1%)
  31/18 (5.6%)4/32 (12.5%)
  4–62/18 (11.1%)2/32 (6.3%)
Preoperative severe arterial damage7 (31.8%)6 (10.3%)0.037*
Follow-up period (months) 8.5 ± 7.6 (2–36)7.7 ± 6.0 (2–29)0.68
 ≥3 months19 (86.4%)49 (84.5%)1.00
 ≥6 months11 (50%)31 (53.4%)0.81
Interval between image and TACE (months)0.084
 <1 month26/29 (89.7%)62/87 (71.3%)
 1-2 months1/29 (3.4%)18/87 (20.7%)
 2-3 months2/29 (6.9%)7/87 (8.0%)

Age is presented as median (range).
AFP, DCP, nodule size, and follow-up period are presented as mean ± standard deviation.
Range of follow-up period is shown in the parentheses.
P < 0.05.
Interval between preoperative image and treatment was evaluated on a per treatment session basis.
HCV: hepatitis C virus; HBV: hepatitis B virus; AFP: alpha-fetoprotein; DCP: des-gamma-carboxyprothrombin; BCLC: Barcelona Clinic Liver Cancer; PS: performance status (Eastern Cooperative Oncology Group classification); TACE: transcatheter arterial chemoembolization; EPI: epirubicin; CDDP: cisplatin; MPT: miriplatin.